 |
| |
Titel: Läkemedelsinformationen måste granskas kritiskt. Industrins enda önskade sluteffekt: Receptet från doktorn till patienten [summary] (serie: Evidensbaserad medicin) 2001 nr 16 sid 1892-7
|
Summary:
Evidence-based drug information
should be preferred
Hans Liedholm, Agneta Björck Linné
Läkartidningen 2001; 98: 1892-7
The purpose of drug information from the pharmaceutical industry is to increase sales. The message is often simplified, short, with emphasis on Unique Selling Points (USP). Information is often given in a pleasant environment, food is served, gifts
handed out. The same information is repeated in advertising campaigns. However, the information is often incomplete and the level of evidence not discussed.
The purpose of producer independent information is to give scientific facts according to the principles practiced by evidence-based medicine. This information focuses on the level of evidence of published papers but is often more lengthy, may be difficult to understand and may even be regarded as boring.
There are, however, useful principles to apply when analysing the information given by the pharmaceutical industry on specific drugs. There are also several sources of independent drug information to turn to.
Correspondence: Hans Liedholm, Universitetssjukhuse MAS, SE-205 02 Malmö, Sweden
(hans.liedholm@smi.mas.lu.se)
Referenser:
1. Brown P. Talking to patients - a dangerous road for industry. Scrip Magazine. July/August 1997:3-4.
2. Bernier CL, Yerkey AN. Cogent Communication: Overcoming Information Overload. Westport, Connecticut: Greenwood Press;1979:39.
3. Silverman M. The epidemiology of drug promotion. Int J Health Serv 1977;7(2):157-66.
4. Bardelay D. French doctors report on sales representatives' visits. Prescrire International 1994;No.17:21.
5. Keng A, Coley RM. Evaluating the accuracy of citations in drug promotional brochures. Ann Pharmacother 1994 Nov;28(11):1231-5.
6. Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. JAMA. 1995 Apr 26;273(16):1296-8.
7. Hedlund F. Granskning av läkemedelsreklam: En av tjugo annonser fälls. Svensk Farmacevtisk Tidskrift, 1995;99:24-7.
8. Barros JA. [Advertising of drugs: risk or benefits]? Gac Sanit 1996 Mar-Apr;10(53):81-90.
9. Lexchin J. What information do physicians receive from pharmaceutical representatives? Can Fam Physician 1997 May;43:941-5.
10. Hemminki E. Content analysis of drug-detailing by pharmaceutical representatives. Med Educ 1977 May;11(3):210-5.
11. Desai NS, Dole EJ, Yeatman ST, Troutman WG. Evaluation of drug information in an Internet newsgroup. J Am Pharm Assoc (Wash) 1997; Jul-Aug;NS37(4):391-4.
12. Roughead EE, Gilbert AL, Harvey KJ. Self-regulatory codes of conduct: are they effective in controlling pharmaceutical representatives' presentations to general medical practitioners? Int J Health Serv 1998;28(2):269-79.
13. Lal A. Information contents of drug advertisements: an Indian experience. Ann Pharmacother 1998 Nov;32(11):1234-8.
14. Barros JA. [(Mis)information on drugs: the double standard practiced by pharmaceutical companies]. Cad Saude Publica 2000 Apr-Jun;16(2):421-7.
15. Helte S. Anmälningar av oetisk reklam slår rekord i år. Dagens Medicin 2000; 12 december:7.
16. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000 Jan 19;283(3):373-80.
17. McCue JD, Hansen CJ, Gal P. Physicians' opinions of the accuracy, accessibility, and frequency of use of ten sources of new drug information. South Med J 1986 Apr;79(4):441-3.
18. Husby T. Legers samarbeid med legemiddelskonulenter. En spørreskjemaundersøkelse. Tidsskr Nor Laegeforen 1991 Sep 20;111(22):2758-60.
19. Sandhu GS, Day RO. Factors affecting prescribing in general practice - a role play. Med J Aust 1992;157:621-2.
20. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. Chest 1992 Jul;102(1):270-3.
21. Lexchin J. Interactions between physicians and the pharmaceutical industry: what does the literature say? CMAJ 1993 Nov 15;149(10):1401-7.
22. Chren MM, Landefeld CS. Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary. JAMA 1994 Mar 2;271(9):684-9.
23. Thomson AN, Craig BJ, Barham PM. Attitudes of general practitioners in New Zealand to pharmaceutical representatives. Br J Gen Pract 1994 May;44(382):220-3.
24. Hodges B. Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks. CMAJ 1995 Sep 1;153(5):553-9.
25. Zarate Cardenas E, Liosa Isenrich L. Prescribing habits of Peruvian physicians and factors influencing them. Bull Pan Am Health Organ 1995 Dec;29(4):328-37.
26. Caudill TS, Johnson MS, Rich EC, McKinney WP. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch Fam Med 1996 Apr;5(4):201-6.
27. Griffith D. Reasons for not seeing drug representatives. BMJ. 1999 Jul 10;319(7202):69-70. No abstract available.
28. Bayliff CD, Edington RD, Johnston LJ, Shaw PW, Bailey DG. Impact of a pharmacist on the educational value of pharmaceutical industry film showings. Can J Hosp Pharm 1991 Dec;44(6):283-7.
29. Ritchie DJ, Manchester RF, Rich MW, Rockwell MM, Stein PM. Acceptance of a pharmacy-based, physician-edited hospital pharmacy and therapeutics committee newsletter. Ann Pharmacother 1992 Jul-Aug;26(7-8):886-9.
30. Berings D, Blondeel L, Habraken H. The effect of industry-independent drug information on the prescribing of benzodiazepines in general practice. Eur J Clin Pharmacol 1994;46(6):501-5.
31. Ekedahl A, Andersson SI, Hovelius B, Molstad S, Liedholm H, Melander A. Drug prescription attitudes and behaviour of general practitioners. Effects of a problem-oriented educational programme. Eur J Clin Pharmacol 1995;47(5):381-7.
32. Lexchin J. Doctors and detailers: therapeutic education or pharmaceutical promotion? Int J Health Serv 1989;19(4):663-79.
33. McKinney WP, Schiedermayer DL, Lurie N, Simpson DE, Goodman JL, Rich EC. Attitudes of internal medicine faculty and residents toward professional interaction with pharmaceutical sales representatives. JAMA1990 Oct 3;264(13):1693-7.
34. Promotional pitfalls. Prescrire International 1992;1:136.
35. The hitch-hiker's guide to promotional drug literature. (Poster). Essential Drugs Monitor 1994;No.17:24.
36. Slawson DC, Shaughnessy AF, Bennett JH. Becoming a medical information master: feeling good about not knowing everything. J Fam Pract 1994 May;38(5):505-13.
37. Shaughnessy AF, Slawson DC, Bennett JH. Separating the wheat from the chaff: identifying fallacies in pharmaceutical promotion. J Gen Intern Med 1994 Oct;9(10):563-8.
38. Shaughnessy AF, Slawson DC, Bennett JH. Becoming an information master: a guidebook to the medical information jungle. J Fam Pract 1994 Nov;39(5):489-99.
39. Shaughnessy AF, Slawson DC, Bennett JH. Teaching information mastery: evaluating information provided by pharmaceutical representatives. Fam Med. 1995 Oct;27(9):581-5.
40. Anastasio GD, Little JM Jr. Pharmaceutical marketing: implications for medical residency training. Pharmacotherapy 1996 Jan-Feb;16(1):103-7.
41. Roughead EE, Harvey KJ, Gilbert AL. Commercial detailing techniques used by pharmaceutical representatives to influence prescribing. Aust N Z J Med 1998 Jun;28(3):306-10.
42. Day R. How to make the most of a visit from a pharmaceutical company representative. Australian Prescriber 2000;23(5):97-9.
43. Sumner D. Lies, damnes lies - or statistics? J Hypertension 1992;10:3-8.
 1892 |
 1893 |
 1894 |
 1895 |
 1896 |
 1897 |